To those that know drug market better then I do
Assuming PAR passed phase 3 for iPps OA and a generic wanted to encroach, would they have to
a.) do trials just on OA patients with their own version of iPps - if so how long (time) from start to finish & how much $$
b.) do a trial to get their iPps version accepted by FDA then do all trials related to OA (like point a.) above (hence 2 different types of trials) - if so how long from start to finish & how much
it's all very complicated but you would assume PAR management would be all over this one would hope
Fiftyone Capital Update, page-23
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $125.6K | 540.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 39178 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 3672 | 2 |
View Market Depth
| Last trade - 12.21pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |